1A
1AD.AU Adalta Ltd
- Market cap
- AUD 6.42M
- P/E
- -
- P/B
- 17.36x
- ROE
- -1,265.3%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 1AD.AU undervalued?
Graham numberThe Graham number of Adalta Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adalta Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-1,265.3%), below 10%.
ROA 0/1
Return on assets (-272.1%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (93.4%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (17.4x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Adalta Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company w…
Full company profileAdalta Ltd financial statements
Adalta Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.80M | 2.02M | 3.54M | 3.85M | 3.99M | 2.76M | 3.47M | 1.74M | 677K | - |
| Gross Profit | 1.79M | 2.02M | 3.51M | -6.40M | 848K | 988K | 3.44M | 1.51M | 457K | - |
| Operating Income | -4.80M | -5.88M | -9.53M | -9.05M | -8.55M | -7.76M | -8.34M | -5.26M | -4.38M | -4.80M |
| EBITDA | -3.00M | -3.86M | -9.38M | -5.85M | -5.50M | -5.92M | -7.58M | -5.26M | -4.38M | -4.80M |
| Net Income | -2.83M | -3.85M | -5.92M | -6.01M | -5.63M | -6.06M | -4.85M | -5.38M | -4.50M | -4.68M |
| EPS | -0.15 | -0.18 | -0.28 | -0.18 | -0.12 | -0.02 | -0.08 | -0.05 | -0.03 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 8.09M | 4.44M | 9.31M | 6.91M | 9.05M | 10.6M | 7.73M | 5.57M | 2.14M | 1.72M |
| Total Liabilities | 345K | 366K | 1.82M | 3.21M | 2.66M | 5.27M | 5.82M | 3.54M | 2.74M | 1.35M |
| Shareholders' Equity | 7.75M | 4.07M | 7.49M | 3.70M | 6.39M | 5.38M | 1.91M | 2.03M | -598K | 370K |
| Cash & Short-term Investments | 6.22M | 2.31M | 5.56M | 3.37M | 5.79M | 8.66M | 4.79M | 3.13M | 1.31M | 1.28M |
| Total Debt | - | - | 2.19M | 2.19M | 1.69M | 4.00M | 4.01M | 2.70M | 1.77M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.73M | -3.93M | -5.82M | -5.89M | -4.78M | -4.09M | -5.13M | -5.26M | -2.94M | -4.44M |
| Capital Expenditure | 6.75K | 3.14K | 171K | 2.38K | 2.12K | 25.2K | 2.13K | 62.4K | 3.00 | 0.00 |
| Free Cash Flow | -3.73M | -3.93M | -5.99M | -5.89M | -4.78M | -4.11M | -5.13M | -5.32M | -2.94M | -4.44M |
| Ratios | ||||||||||
| ROE | -36.6% | -94.7% | -79.0% | -162.2% | -88.1% | -112.7% | -254.0% | -265.0% | - | -1,265.3% |
| ROA | -35.0% | -86.8% | -63.6% | -87.0% | -62.2% | -56.9% | -62.7% | -96.6% | -210.2% | -272.1% |
| Net Profit Margin | -157.6% | -190.8% | -167.2% | -156.1% | -141.2% | -220.0% | -139.8% | -309.7% | -665.0% | - |
| Debt to Equity | - | - | 0.29x | 0.59x | 0.26x | 0.74x | 2.10x | 1.33x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adalta Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | AUD 2.76M | 0.01 | - |
| 2021 | AUD 5.18M | 0.11 | - |
| 2020 | AUD 3.55M | 0.11 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Dec 8, 2025.
Who owns Adalta Ltd
- Insiders 56.81%
- Institutions 2.34%
- Public & others 40.86%
- Shares outstanding 3.21B
- Free float 1.38B
Adalta Ltd company profile
- Company name
- Adalta Ltd
- Ticker
- 1AD.AU
- ISIN
- AU0000001AD2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- June
- Address
- 117 Camberwell Road, Hawthorn East, VIC, Australia, 3123
- Phone
- 61 3 9479 5159
- Website
- adalta.com.au
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
Adalta Ltd management
7- Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.CEO, MD & Director
- Mr. Angus Tester Ph.D.Senior Director of Operations
- Prof. Michael Foley Ph.D.Founding Chief Scientist
- Dr. Andrew Peter O'Brien MBA., Ph.D.Head of Corporate Development · born 1969
- Ms. Janette DixonHead of Business Development
- Dr. Kevin Patrick Lynch FFPM, M.D., MBBSConsultant Chief Medical Officer of Oncology · born 1965
- Mr. Cameron Peter Jones C.A.Company Secretary